Sphere Fluidics’ second-generation Cyto-Mine Chroma will offer enhanced capabilities, including multiplexing and greater assay flexibility to further maximize the efficiency and precision of single-cell functional analysis workflows. The platform builds on the original Cyto-Mine platform’s ability to leverage picodroplet technology to encapsulate single cells, assess cellular function, and isolate target cells for downstream expansion or analysis. The new Chroma system will maintain excellent throughput, enabling functional screening of millions of cells per hour and expand its multiplexing capabilities. Launching in conjunction with the company’s first multiplexed assay kit, the platform will enable researchers to conduct multiplexing in a single droplet, improving the throughput and precision of clone selection, by analyzing single cells for viability, productivity, and target specificity in one step. By accelerating the early selection of superior candidate cells, overall project timelines can be reduced from months to weeks, while reducing effort and cost.
Cyto-Mine Chroma, which will launch in Q1 2025, is designed to support evolving needs in single cell analysis, facilitating cutting-edge, cost-effective research across broad applications, including antibody discovery, cell line development, and emerging areas such as cell therapy.